77 results
8-K
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
license application resubmission strategy for cosibelimab.
A copy of such press release is being furnished as Exhibit 99.1 to this report.
Item 9.01
8-K
EX-99.1
CKPT
Checkpoint Therapeutics Inc
24 Jun 24
Checkpoint Therapeutics Announces Alignment with FDA Enabling Upcoming Cosibelimab BLA Resubmission
7:46am
alignment with the Food and Drug Administration (“FDA”) on its biologics license application (“BLA”) resubmission strategy for cosibelimab … BLA resubmission strategy to potentially address all approvability deficiencies outlined in the complete response letter (“CRL”) received last December
8-K
EX-99.1
rbv4vylp1o8
5 Dec 22
Checkpoint Therapeutics Announces Reverse Stock Split
4:45pm
8-K
EX-99.1
igcvxjmql1y
8 Nov 22
Checkpoint Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights
5:43pm
8-K
EX-99.1
kn3nmkbf
12 Aug 22
Checkpoint Therapeutics Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights
8:15am
8-K
EX-99.1
9sg 0vvh1hcrsz60yz40
12 May 22
Checkpoint Therapeutics Reports First Quarter 2022 Financial Results and Recent Corporate Highlights
4:45pm
8-K
EX-99.1
9h06h zjb
28 Mar 22
Checkpoint Therapeutics Reports Full-Year 2021 Financial Results and Recent Corporate Highlights
7:53am
8-K
EX-99.1
6dako69upa70
4 Nov 21
Checkpoint Therapeutics Reports Third Quarter 2021 Financial Results
4:44pm